(原著)（２００２年）
１. Schwarz-Lauer LL, Chazenbalk GD, MacLachlan SM, Ochi Y,Nagayama Y, Rapoport B. Evidence for a simplified view ofautoantibody interactions with the TSH receptor. Thyroid.
12 (2): 115-120, 2002.
2. Nagayama Y, Kita-Furuyama M, Nakao K, Ando T, Mizuguchi
H, Hayakawa T, Eguchi K, Niwa M. A novel murine model ofGraves’ hyperthyroidism with intramuscular injection of
adenovirus expressing thyrotropin receptor. J Immunol.
168(6): 2789-2794, 2002.
3. Kakinuma A, Nagayama Y. Multiple messenger ribonucleic
acid transcripts and revised gene organization of human TSH
receptor. Endocrine J. 49(2): 175-180, 2002.
4. Kuroda H, Ohtsuru A, Futakuchi M, Kawashita Y, Nagayama
Y, Fukuda E, Namba H, Shirai T, Kanematsu T, Yamashita S.
Distinctive gene expression of receptor-type tyrosine
kinase families during rat hepatocarcinogenesis. Int J Mol
Med. 9 (5): 473-480, 2002.
5. Kawamata Y, Nagayama Y, Nakao K, Mizuguchi H, Hayakawa
T, Ishii N. Receptor-independent augmentation ofadenovirus-mediated gene transfer with chitosan in vitro.
Biomaterials. 23 (23): 4573-4579, 2002.
6. Tamada Y, Nakao K, Nagayama Y, Ichikawa T, Kawamata Y,Hamasaki K, Nakata K, Eguchi K, Ishii N. p48 overexpression
enhances interferon-mediated expression and activity of
double-stranded RNA-dependent protein kinase (PKR) in humanhepatoma cells. J Hepatol. 37 (4): 493-499, 2002.

7. Ando T, Latif R, Prisker A, Moran T, Nagayama Y, Davies
TF. A monoclonal thyroid-stimulating antibody. J ClinInvest. 110 (11): 1667-1674, 2002.
8. Ito M, Nakashima M, Nakayama T, Ohtsuru A, Nagayama Y,Takamura N, Demedchik EP, Sekine I, Yamashita S. Expressionof receptor-type tyrosine kinase, Axl, and its ligand,Gas6, in pediatric thyroid carcinomas around Chernobyl.
Thyroid. 12 (11): 971-975, 2002.

（２００３年）
1. Yanagi K, Nagayama Y, Nakao K, Saeki A, Matsumoto K,
Ohata K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N,Eguchi K. Immuno-gene therapy with adenoviruses expressing
fms-like tyrosine kinase 3 ligand and CD40 ligand for mousehepatoma cells in vivo. Int J Oncol. 22(2): 345-351, 2003.
2. Kita-Furuyama M, Nagayama Y, Pichurin P, McLachlan SM,Rapoport B, Eguchi K. Dendritic cells infected withadenovirus expressing the thyrotropin receptor induce
Graves’ hyperthyroidism in BALB/c mice. Clin Exp Immunol.
131(2): 234-240, 2003.
3. Nagayama Y, McLachlan SM, Rapoport B, Niwa M. A majorrole for non-major histocompatibility complex genes but notfor microorganisms in a novel murine model of Graves’
hyperthyroidism. Thyroid. 13(3): 233-238, 2003.
4. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan
SM, Rapoport B. Prevention of autoantibody-mediatedGraves’-like hyperthyroidism in mice by IL-4, a Th2cytokine. J Immunol. 170 (7): 3522-3527, 2003.
5. Kita A, Uotani S, Kuwahara H, Takahashi R, Oshima K,Yamasaki H, Mizuguchi H, Hayakawa T, Nagayama Y, Yamaguchi
Y, Eguchi K. Vanadate enhances leptin-induced activation ofJAK/STAT pathway in CHO cells. Biochem Biophys Res Commun.
302(4): 805-809, 2003.
6. Schwarz-Lauer L, Pichurin P, Chen C-R, Nagayama Y, ParasC, Morris JC, Rapoport B, McLachlan SM. The cysteine-richamino-terminus of the thyrotropin receptor is theimmunodominant linear antibody epitope in mice immunizedusing naked DNA or adenovirus vectors. Endocrinology. 144(5): 1718-1725, 2003.

7. Guo J, Pichurin P, Nagayama Y, Rapoport B, McLachlan SM.
Insight into antibody responses induced by plasmid or
adenoviral vectors encoding thyroid peroxidase, a major
thyroid autoantigen. Clin Exp Immunol. 132 (3): 408-415,
2003.
8. Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B,McLachlan SM. The thyrotropin receptor autoantigen in
Graves’ disease is the culprit as well as the victim. JClin Invest. 111 (12): 1897-1904, 2003.
9. Nagayama Y, Nakao K, Mizuguchi H, Hayakawa T, Niwa M.
Enhanced antitumor effect of combined replicativeadenovirus and non-replicative adenovirus expressing
interleukin-12 in an immunocompetent mouse model. Gene
Therapy. 10 (16): 1400-1403, 2003.
10. Nagayama Y. Novel murine models of thyroid
autoimmunity. Current Opinion in Endocrinology & Diabetes.
10: 364-370, 2003.
11. Abiru N, Sun F, Kawasak E, Yamasaki H, Oshima K,Nagayama Y, Mizuguchi H, Hayakawa T, Miao D, Liu E,
Eisenbarth GS, Eguchi K. In vivo expression of B:923
peptide/I-Ag7 complex may abrogate the inhibition ofdiabetes induced by RGD-fiber-mutant adenovirus in NOD
mice. Ann NY Acad Sci. 1005: 218-221, 2003.
12. Pichurin P, Aliesky H, Chen C-R, Nagayama Y, Rapoport
B, McLachlan SM. Thyrotropin receptor-specific memory T
cell responses require normal B cells in a murine model ofGraves’ disease. Clin Exp Immunol. 134 (3): 396-402, 2003.
13. Saeki A, Nakao K, Nagayama Y, Yanagi K, Matsumoto K,Hayashi T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K.
Diverse efficacy of vaccination therapy using the α-fetoprotein gene against hepatocellular carcinoma. Int JOncol. 13 (1): 111-116, 2003.
14. Tanaka K, Towata S, Nakao K, Mizuguchi H, Hayakawa T,Niwa M, Ishii N, Nagayama Y. Thyroid cancer immunotherapy
with retroviral and adenoviral vectors expressing
granulocyte-macrophage colony stimulating factor andinterleukin-12 in a rat model. Clin Endocrinol. 59 (6):734-742, 2003.

（２００４年）
1. Chen C-R, Pichurin P, Chazenbalk GD, Aliesky H, Nagayama
Y, McLachlan SM, Rapoport B. Low dose immunization withadenovirus expressing the TSH receptor A-subunit deviates
the antibody response towards that of autoantibodies inhuman Graves’ disease. Endocrinology. 145 (1): 228-233,2004.
2. Pichurin PN, Chen CR, Nagayama Y, Pichurina O, Rapoport
B, McLachlan SM. Evidence that factors other thanparticular thyrotropin receptor T cell epitopes contributeto the development of hyperthyroidism in murine Graves'disease. Clin Exp Immunol. 135 (3): 391-397, 2004.
3. Sundaresan G, Paulmurugan R, Berger F, Stiles B, Nagayama
Y, Wu H, Gambhir SS. MicroPET imaging of Cre-loxP mediatedconditional activation of a PET reporter gene. Gene Ther.
11 (7): 609-618, 2004.
4. Nagayama Y, Niwa M, McLachlan SM, Rapoport B.
Schistosoma mansoni and α-galactosylceramide: prophylactic
effect of Th2 immune deviation in a mouse model of Graves’hyperthyroidism. J Immunol.173 (3): 2167-2173, 2004.
5. Chen RC-R, Aliesky H, Pichurin PN, Nagayama Y, McLachlan
SM, Rapoport B. Susceptibility rather than resistance tohyperthyroidism is dominant in a thyrotropin receptor
adenovirus-induced animal model of Graves’ disease asrevealed by BALB/c-C57BL/6 hybrid mice. Endocrinology. 145(11): 4927-4933, 2004.

6. Nagayama Y, McLachlan SM, Rapoport B, Oishi K. Graves’
hyperthyroidism and the hygiene hypothesis in a mousemodel. Endocrinology. 145 (11): 5075-5079, 2004.
7. Nagayama Y, Saitoh O, McLachlan SM, Rapoport B, Kano H,Kumazawa Y. TSH receptor-adenovirus-induced Graves’ disease
is attenuated in both interferon-γ and interleukin-4
knockout mice; implications for the Th1/Th2 paradigm. Clin
Exp Immunol. 138 (3): 417-422, 2004.

（２００５年）
1. Hayashi T, Nakao K, Nagayama Y, Saitoh O, Ichikawa T,Ishikawa H, Hamasaki K, Eguchi K, Ishii N. Vaccination withdendritic cells pulsed with apoptotic cells elicits
effective antitumor immunity in murine hepatoma models. IntJ Oncol. 26 (5): 1313-1319, 2005.
2. Nagayama Y. Animal model of Graves’ disease. Acta MedNagasaki. 50 (6): 49-53, 2005.
3. Saitoh O, Mizutori Y, Takamura N, Kita A, Kuwahara H,Yamasaki H, Nagayama Y. Adenovirus-mediated gene deliveryof interleukin-10, but not transforming growth factor b,
ameliorates Graves’ hyperthyroidism in BALB/c mice. Clin
Exp Immunol. 141 (3): 405-411, 2005.
4. Nagayama Y. Animal models of Graves’ hyperthyroidism.
Endocr J. 52 (4): 385-394, 2005.
5. McLachlan SM, Nagayama Y, Rapoport B. Insight into
Graves’ hyperthyroidism from animal models. Endocr Rev.
26(6): 800-832, 2005.

（２００６年）
1. Mizutori Y, Saitoh O, Eguchi K, Nagayama Y. Adenovirus
coding the thyrotropin receptor A subunit improves theefficacy of dendritic cell-based mouse model of Graves’
hyperthyroidism. J Autoimmunity. 26 (1): 32-36, 2006.
2. Saitoh O, Nagayama Y. Regulation of Graves’
hyperthyroidism with naturally occurring CD4+CD25+
regulatory T cells in a mouse model. Endocrinology.
147(5):2417-2422, 2006.
3. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K,Ishii N, Nagayama Y, Eguchi K. Different mechanisms foranti-tumor effects of low- and high-dose cyclophosphamide.
Submitted to Int J Oncol.

(２００７年)
1. Nagayama Y, Hase W, Motoyoshi Y, Saitoh O, Sogawa R,Nakao K. Distinct responses of two hepatocellular carcinoma
cell lines of a similar origin to immunotherapies targeting
regulatory or effector T cells. Oncol Rep. 17 (5): 12691273, 2007.
2. Moriuchi A, Yamasaki H, Shimamura M, Kita A, Kuwahara H,Fujishima K, Satoh T, Fukushima K, Fukushima T, Hayakawa T,Mizuguchi H, Nagayama Y, Abiru N, Kawasaki E, Eguchi K.
Induction of human adiponectin gene transcription bytelmisartan, angiotensin receptor blocker, independently on
PPAR-g activation. Biochem Biophys Res Com. 356 (4):102430, 2007.
3. Mizutori Y, Saitoh O, Eguchi K, Nagayama Y. Lack ofeffect of methimazole on dendritic cell (DC) function and
DC-induced Graves’ hyperthyroidism in mice. Autoimmunity.
40 (5): 397-402, 2007.
4. Nagayama Y, Horie I, Saitoh O, Nakahara M, Abiru N.
CD4+CD25+ naturally occurring regulatory T cells and not
lymphopenic proliferation play a role in the pathogenesisof experimental autoimmune thyroiditis in NOD-H2h4 mice. JAutoimmun. 29(2-3): 195-202 2007.

5. Nagayama Y. Animal models of Graves’ hyperthyroidism.
Thyroid. 17 (10): 981-988, 2007.
6. Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+CD122+ Tcells, a newly identified regulatory T cells, negativelyregulate Graves’ disease in a murine model. Endocrinology.
148 (12): 6040-6046, 2007.
7. McLachlan SM, Nagayama Y, Pichurin PN, Mizutori Y, Chen
C-R, Misharin A, Aliesky HA, Rapoport B. The link between
Graves’ disease and Hashimoto’s thyroiditis: a role forregulatory T cells. Endocrinology. 148 (12): 5724-5733,2007.
8. Nishihara E, Nagayama Y, Amino N, Hishinuma A, Yoshida
H, Kubota S, Fukata S, Kuma K, Miyauchi A. Novel
thyrotropin receptor germline mutation (Asp617Tyr) causing
hereditary hyperthyroidism with adult onset in a Japanesefamily. Endocrine J. 54 (6): 927-934, 2007.
9. Sedliarou I, Matsuse M, Saenko V, Rogounovitch T,Nakazawa Y, Mitsutake N, Namba H, Nagayama Y, Yamashita S.
Overexpression of wild-type THRbeta1 suppresses the growthand invasiveness of human papillary thyroid cancer cells.
Anticancer Res. 27(6B):3999-4009, 2007.

(２００８年)
1. Fukushima K, Kobayashi M, Nagayama Y, Satoh T, Nakahara
M, Kawasaki E, Yamasaki H, Ueha S, Matsushima K, Liu E,
Eisenbarth GS, Eguchi K, Abiru N. Combined activation ofinnate and adaptive immunity with polyinosinicpolycytidylic acid and insulin B:9-23 self-peptide in thegenetically susceptible NOD mouse: differential effects oninsulitis and diabetes progression. Biochem Biophys ResCommun. 367 (4): 719-724, 2008.
2. Nagayama Y, Kaminoda K, Mizutori Y, Saitoh O, Abiru N.
Exacerbation of autoimmune thyroiditis by a single dose ofwhole body irradiation in NOD-H2h4 mice. Int J Radiat Biol.
84 (9): 761-769, 2008.
3. Mizutori Y, Nagayama Y, Flower D, Misharin A, Aliesky
HA, Rapoport B, McLachlan SM. Role of the human A-subunitin transgenic mice that develop thyroid lymphocytic
infiltration after immunization and regulatory T cell
depletion. Clin Exp Immunol. 154 (3): 305-315, 2008.
4. Nagayama Y. Mouse models of Graves’ disease. The
Proceeding for 13th International Congress ofEndocrinology. 115-118, 2008.

（２００９年）
1. Nakahara M, Nagayama Y, Sogawa R, Saitoh O, Tone S,
Abiru N. Expression of immuno-regulatory molecules on thethyrocytes protects NOD-H2h4 mice from developing
autoimmune thyroiditis. Endocrinology. 150 (3): 1545-1551,2009.
2. Misharin A, Aliesky H, Nagayama Y, Rapoport B, McLachlan
SM. Studies in mice deficient for the Autoimmune Regulator(Aire) and transgenic for the thyrotropin receptor reveal arole for Aire in tolerance for thyroid autoantigens.
Endocrinology. 150 (6): 2948-2956, 2009.
3. Misharin AV, Nagayama Y, Holly A. Aliesky AH, Mizutori
Y, Rapoport B, McLachlan SM. Attenuation of induced
hyperthyroidism in mice by pre-treatment with thyrotropin
receptor protein: diversion of thyroid stimulating antibody
to non-functional antibody induction. Endocrinology. 150(8): 3944-3952, 2009.
4. Saitoh O, Mitsutake N, Nakayama T, Nagayama Y.
Fibroblast-mediated in vivo and in vitro growth promotionof thyroid carcinoma FTRL-Tc, not normal thyroid FRTL5,cells. Thyroid. 19(7):735-742, 2009.

5. Horie I, Abiru N, Nagayama Y, Saitoh O, Ichikawa T,
Iwakura Y, Eguchi K. T helper type 17 immune response plays
an indispensable role for development of experimental
autoimmune thyroiditis in NOD-H2h4 mice. Endocrinology. 150(11): 5135-5142, 2009.
6. Nagayama Y, Ichikawa T, Saitoh O, Abiru N. Induction oflate-onset, spontaneous autoimmune thyroiditis by a single
low-dose irradiation in non-obese diabetic-H2h4 mice. J
Radiat Res. 50 (6): 573-577, 2009.